세계의 저분자 이노베이터 CDMO 시장 : 시장 규모, 점유율 및 동향 분석(제품별, 단계 유형별, 치료 영역별, 고객 유형별, 지역별), 부문별 예측(2025-2033년)

Small Molecule Innovator CDMO Market Share & Trends Analysis Report By Product (Small Molecule API, Small Molecule Drug Product), By Stage Type (Clinical, Commercial), By Therapeutic Area, By Customer Type, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,467,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,890,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,736,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

저분자 이노베이터 CDMO 시장 개요

전 세계 저분자 이노베이터 CDMO 시장 규모는 2024년 413억 9,000만 달러로 평가되었습니다. 2033년에는 693억 8,000만 달러에 달하고, 2025-2033년 6.07%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

신흥국 시장의 성장 배경에는 특히 저분자 영역에서 제약기업의 의약품 개발 및 제조 아웃소싱이 증가하고 있다는 점이 있습니다.

의약품 파이프라인이 복잡해지고 규제 당국의 감시가 강화됨에 따라 제약사들은 원료 합성, 제형 개발, 임상 규모 생산 등의 전문 서비스를 제공하는 CDMO에 대한 의존도가 높아지고 있습니다. 시장을 주도하고 있는 것은 업무 효율화, 사내 제조 부담 감소, 의약품 개발 기간 단축을 목표로 하는 제약사들 사이에서 아웃소싱에 대한 의존도가 높아지고 있다는 점입니다. 혁신 기업, 특히 인프라가 제한적인 신생 생명공학 기업들은 초기 개발부터 상업 생산에 이르기까지 CDMO의 전문 서비스를 찾는 경향이 증가하고 있습니다. 이러한 추세는 규제 준수의 복잡성, 고활성 원료를 위한 고도의 봉쇄 시설의 필요성, 내부 역량 유지에 따른 높은 비용으로 인해 더욱 강화되고 있습니다. 암, 감염성 질환, 희귀질환을 대상으로 한 임상시험과 신규 분자 화합물(NME) 증가는 cGMP 조건에서 고품질 원료의약품 제조, 분석 시험, 제형 개발 전문성을 제공하는 CDMO에 대한 수요를 증가시키고 있습니다.

목차

제1장 분석 방법, 범위

제2장 주요 요약

제3장 저분자 이노베이터 CDMO 시장 : 변동 요인, 동향 및 범위

• 시장 연관 전망
• 저분자 이노베이터 CDMO 시장 역학
• 기술적 상황
• 가격 모델 분석
• 저분자 이노베이터 CDMO 시장 : 분석 툴

제4장 저분자 이노베이터 CDMO 시장 : 제품별 추정 및 동향 분석

• 부문 대시보드
• 세계의 저분자 이노베이터 CDMO 시장 : 변동 분석, 제품별
• 세계의 저분자 이노베이터 CDMO 시장 규모와 동향 분석 : 제품별(2021-2033년)
• 저분자 API
• 저분자 의약품
  • 경구 고형제
  • 반고형제
  • 액체 투여제
  • 기타

제5장 저분자 이노베이터 CDMO 시장 : 단계 유형별 추정 및 동향 분석

• 부문 대시보드
• 세계의 저분자 이노베이터 CDMO 시장 : 변동 분석, 단계 유형별
• 세계의 저분자 이노베이터 CDMO 시장 규모와 동향 분석 : 단계 유형별(2021-2033년)
• 전임상
• 임상
  • 제I상
  • 제II상
  • 제III상
• 출시

제6장 저분자 이노베이터 CDMO 시장 : 고객 유형별 추정 및 동향 분석

• 부문 대시보드
• 세계의 저분자 이노베이터 CDMO 시장 : 변동 분석, 고객 유형별
• 세계의 저분자 이노베이터 CDMO 시장 규모와 동향 분석 : 고객 유형별(2021-2033년)
• 제약
  • 소기업
  • 중기업
  • 대기업
• 바이오테크놀러지

제7장 저분자 이노베이터 CDMO 시장 : 치료 영역별 추정 및 동향 분석

• 부문 대시보드
• 세계의 저분자 이노베이터 CDMO 시장 : 변동 분석, 치료 영역별
• 세계의 저분자 이노베이터 CDMO 시장 규모와 동향 분석 : 치료 영역별(2021-2033년)
• 심혈관질환
• 종양학
• 호흡기질환
• 신경학
• 대사장애
• 감염증
• 기타

제8장 저분자 이노베이터 CDMO 시장 : 지역별 추정, 동향 분석(제품별, 약제 유형별, 용도별)

• 시장 대시보드 : 지역별
• 세계 시장 스냅숏 : 지역별
• 시장 규모 예측과 동향 분석(2021-2033년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 기업 분류
• 저분자 이노베이터 CDMO 시장 점유율 분석(2024년)
• 기업 개요
  • Piramal Pharma Solutions
  • CordenPharma International
  • Wuxi AppTec
  • Cambrex Corporation
  • Recipharm AB
  • Thermo Fisher Scientific, Inc.
  • Lonza
  • Catalent Inc.
  • Siegfried Holding AG
  • Boehringer Ingelheim
  • Labcorp

LSH

영문 목차

영문목차

Small Molecule Innovator CDMO Market Summary

The global small molecule innovator CDMO market size was estimated at USD 41.39 billion in 2024 and is projected to reach USD 69.38 billion by 2033, growing at a CAGR of 6.07% from 2025 to 2033. The growth of the market is due to the increasing outsourcing of drug development and manufacturing by pharmaceutical innovators, particularly in the small molecule space.

As drug pipelines become more complex and regulatory scrutiny tightens, pharmaceutical companies are relying more on CDMOs to provide specialized services such as API synthesis, formulation development, and clinical-scale production. The market is driven by a growing reliance on outsourcing among pharmaceutical companies aiming to streamline operations, reduce internal manufacturing burdens, and accelerate drug development timelines. Innovator companies, especially emerging biotechs with limited infrastructure, increasingly turn to CDMOs for specialized services ranging from early-phase development to commercial manufacturing. This trend is reinforced by the complexity of regulatory compliance, the need for advanced containment facilities for potent APIs, and the high costs associated with maintaining in-house capabilities. The rise in clinical trials and new molecular entities (NMEs) targeting oncology, infectious diseases, and rare disorders is pushing demand for CDMOs that offer high-quality API production, analytical testing, and formulation development expertise under cGMP conditions.

Global Small Molecule Innovator CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule innovator CDMO market report based on product, stage type, customer type, therapeutic area, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Small Molecule API
• Small Molecule Drug Product
  • Oral Solid Dose
  • Semi-Solid Dose
  • Liquid Dose
  • Others
• Stage Type Outlook (Revenue, USD Million, 2021 - 2033)
• Preclinical
• Clinical
  • Phase I
  • Small
  • Medium
  • Large
  • Phase II
  • Small
  • Medium
  • Large
  • Phase III
  • Small
  • Medium
  • Large
• Commercial
• Customer Type Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical
  • Small
  • Medium
  • Large
• Biotechnology
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Cardiovascular Diseases
• Oncology
• Respiratory Disorders
• Neurology
• Metabolic Disorders
• Infectious Diseases
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Norway
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Value chain based analysis (Model 2)
  • 1.7.3. Multivariate Analysis (Model 3)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Small Molecule Innovator CDMO Market: Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Small Molecule Innovator CDMO Market Dynamics
  • 3.2.1. Market Driver Impact Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technological Landscape
• 3.4. Pricing Model Analysis
• 3.5. Small Molecule Innovator CDMO Market: Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL Analysis

Chapter 4. Small Molecule Innovator CDMO Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Small Molecule Innovator CDMO Market Product Movement Analysis
• 4.3. Global Small Molecule Innovator CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Small Molecule API
  • 4.4.1. Small Molecule API Market Estimates and Forecasts, 2021 - 2033 (USD million)
• 4.5. Small Molecule Drug Product
  • 4.5.1. Small Molecule Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5.2. Oral Solid Dose
    • 4.5.2.1. Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5.3. Semi-Solid Dose
    • 4.5.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5.4. Liquid Dose
    • 4.5.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5.5. Others
    • 4.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD million)

Chapter 5. Small Molecule Innovator CDMO Market: Stage Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Small Molecule Innovator CDMO Market Stage Type Movement Analysis
• 5.3. Global Small Molecule Innovator CDMO Market Size & Trend Analysis, by Stage Type, 2021 to 2033 (USD Million)
• 5.4. Preclinical
  • 5.4.1. Preclinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Clinical
  • 5.5.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Phase I
    • 5.5.2.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.2.2. Small
      • 5.5.2.2.1. Small Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.2.3. Medium
      • 5.5.2.3.1. Medium Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.2.4. Large
      • 5.5.2.4.1. Large Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 5.5.3. Phase II
    • 5.5.3.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.3.2. Small
      • 5.5.3.2.1. Small Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.3.3. Medium
      • 5.5.3.3.1. Medium Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.3.4. Large
      • 5.5.3.4.1. Large Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 5.5.4. Phase III
    • 5.5.4.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.4.2. Small
      • 5.5.4.2.1. Small Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.4.3. Medium
      • 5.5.4.3.1. Medium Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 5.5.4.4. Large
      • 5.5.4.4.1. Large Market Estimates and Forecasts, 2021 - 2033 (USD million)
• 5.6. Commercial
  • 5.6.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Small Molecule Innovator CDMO Market: Customer Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Small Molecule Innovator CDMO Market Customer Type Movement Analysis
• 6.3. Global Small Molecule Innovator CDMO Market Size & Trend Analysis, by Customer Type, 2021 to 2033 (USD Million)
• 6.4. Pharmaceutical
  • 6.4.1. Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Small
    • 6.4.2.1. Small Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Medium
    • 6.4.3.1. Medium Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Large
    • 6.4.4.1. Large Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Biotechnology
  • 6.5.1. Biotechnology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Small Molecule Innovator CDMO Market: Therapeutic Area Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Small Molecule Innovator CDMO Market Therapeutic Area Movement Analysis
• 7.3. Global Small Molecule Innovator CDMO Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
• 7.4. Cardiovascular diseases
  • 7.4.1. Cardiovascular diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Oncology
  • 7.5.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Respiratory disorders
  • 7.6.1. Respiratory disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Neurology
  • 7.7.1. Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Metabolic Disorders
  • 7.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Infectious Diseases
  • 7.9.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.10. Others
  • 7.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Small Molecule Innovator CDMO Market: Regional Estimates & Trend Analysis by Product, Drug Type, Application

• 8.1. Regional Market Dashboard
• 8.2. Global Regional Market Snapshot
• 8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Small Molecule Innovator CDMO Market Share Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. Piramal Pharma Solutions
    • 9.3.1.1. Company overview
    • 9.3.1.2. Financial performance
    • 9.3.1.3. Product benchmarking
    • 9.3.1.4. Strategic initiatives
  • 9.3.2. CordenPharma International
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Wuxi AppTec
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Cambrex Corporation
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Recipharm AB
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Thermo Fisher Scientific, Inc.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Lonza
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Catalent Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Siegfried Holding AG
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Boehringer Ingelheim
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Labcorp
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives

관련자료